The CAFs also express the sst1 somatostatin receptor, whose activation inhibits the mTOR/4E-BP1 pathway, which in turn modulates the synthesis of the secreted proteins involved in the resistance to cancer drug therapies, including IL-6 and STAT3, and could be a possible upstream regulator of the IL-6 expression. The gene discussed is IL6; the disease is cancer.